PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study

NCT07874828 on ClinicalTrials.gov · last registry update 2026-10-15

A small phase 2 — 30 participants, against a typical 110. Due to report 31 December 2034. Primary outcome, as filed: Safety and Adverse Events (AEs). Sponsors move these dates routinely; any movement since this site started watching is listed below. The registry entry has been edited 1 time since then.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: M.D. Anderson Cancer Center
Sponsor type: Other
Enrollment: 30
Started: 2026-12-31
Primary completion: 2034-12-31 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-10-15	First seen in registry	Registered as NOT_YET_RECRUITING, P2

Primary outcome

Safety and Adverse Events (AEs)

Conditions studied

Sarcoma,Soft Tissue

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.